CIBC Private Wealth Group
SMMT icon

CIBC Private Wealth Group’s Summit Therapeutics SMMT Stock Holding History

CIBC Private Wealth Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$52 Buy
+3
New +$56 ﹤0.01% 3331

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CIBC Private Wealth Group's SMMT Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Summit Therapeutics (SMMT) in Q4 2025: 3 shares worth $52. The stake represents ﹤0.01% of the portfolio and ranks #3331 among its holdings.

206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • CIBC Private Wealth Group held 3 shares of Summit Therapeutics worth $52 as of Q4 2025.
  • Summit Therapeutics was a new CIBC Private Wealth Group position in Q4 2025.
  • Summit Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3331 holding.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.